Iovance Biotherapeutics, Inc. (IOVA) Analyst Estimates Annual - Discounting Cash Flows
IOVA
Iovance Biotherapeutics, Inc.
IOVA (NASDAQ)
Period Ending: 2029
12-31
2028
12-31
2027
12-31
2026
12-31
2025
12-31
2024
12-31
2023
12-31
2020
12-31
Number of Analysts 7 6 8 8 7 10 10 19
Estimated Revenue
Low 873.7 742.5 598.4 371.6 234.8 160.3 1.79 27.59
Average 967 821.8 607.3 425.4 259.9 162.5 4.42 34.49
High 1,090 926.3 616.2 476.9 292.9 168.4 10.74 41.39
Estimated EBITDA
Low 174.7 148.5 119.7 74.31 46.96 32.05 0.358 -318.5
Average 193.4 164.4 121.5 85.09 51.98 32.49 0.885 -265.4
High 218 185.3 123.2 95.39 58.59 33.67 2.15 -212.3
Estimated EBIT
Low 174.7 148.5 119.7 74.31 46.96 32.05 0.358 -319.9
Average 193.4 164.4 121.5 85.09 51.98 32.49 0.885 -266.6
High 218 185.3 123.2 95.39 58.59 33.67 2.15 -213.3
Estimated Net Income
Low 115.8 67.18 -197 -241.9 -355.7 -402.8 -548.1 -317.1
Average 132.4 76.82 -99.53 -165.6 -311.5 -389.9 -538 -264.2
High 154.3 89.52 73.54 -89.23 -267.4 -259.4 -527.9 -211.4
Estimated SGA Expenses
Low 16,400 13,938 11,232 6,974 4,407 3,008 33.61 414.4
Average 18,151 15,426 11,399 7,986 4,878 3,050 83.01 518.1
High 20,459 17,388 11,567 8,952 5,498 3,160 201.7 621.7
Estimated EPS
Low 0.399 0.232 -0.68 -0.834 -1.23 -1.39 -1.89 -1.92
Average 0.457 0.265 -0.18 -0.575 -1.1 -1.29 -1.87 -1.85
High 0.532 0.309 0.254 -0.308 -0.922 -0.895 -1.82 -1.75
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us
Want to become our sponsor?
Check out our Affiliate Program